Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-galactosidase is an **enzyme** that hydrolyzes terminal, non-reducing α-D-galactose residues in oligosaccharides, polysaccharides, glycolipids, and glycoproteins, facilitating the digestion of complex carbohydrates and helping to prevent gas, bloating, and digestive discomfort caused by undigested carbohydrates. It is used as an **over-the-counter digestive enzyme supplement**, as well as in enzyme replacement therapy for Fabry disease (where recombinant forms are used). The enzyme is produced industrially from sources like *Aspergillus niger* for dietary supplements. The mechanism of action involves cleavage of α-1,6 and α-1,3 linked galactosides, thereby reducing fermentable carbohydrates that cause gas production in the intestine. In human genetics, deficiency leads to Fabry disease, but in dietary supplements the enzyme is aimed at aiding digestion and reducing flatulence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-galactosidase.